Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 4Takayasu Arteritis 1Skin Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Inflammation 1Hematologic Neoplasms 1Fatigue 1Drug-Related Side Effects and Adverse Reactions 1Depressive Disorder, Major 1Depression 1Colitis 1Cognitive Dysfunction 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anorexia 1Anemia 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × Infliximab × Clear all
NCT02763761 2018-10-09

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Bristol-Myers Squibb

Phase 2 Withdrawn
DermatologicGenitourinaryThoracic

Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡